Literature DB >> 32463329

Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.

Tiziana Carandini1, Anna Margherita Pietroboni1, Luca Sacchi1,2, Milena Alessandra De Riz1, Mattia Pozzato1,2, Andrea Arighi1, Giorgio Giulio Fumagalli1, Filippo Martinelli Boneschi1,2, Daniela Galimberti1,2, Elio Scarpini1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32463329     DOI： 10.1177/1352458520926459

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  12 in total

Review 1.  Immunology of COVID-19 and disease-modifying therapies: The good, the bad and the unknown.

Authors:  Tobias Zrzavy; Isabella Wimmer; Paulus S Rommer; Thomas Berger
Journal:  Eur J Neurol       Date:  2020-11-08       Impact factor: 6.288

2.  Multiple sclerosis and COVID-19: How could therapeutic scenarios change during the pandemic?

Authors:  Vittorio Mantero; Lucia Abate; Andrea Salmaggi; Christian Cordano
Journal:  J Med Virol       Date:  2021-01-22       Impact factor: 2.327

Review 3.  [Neuroimmunology of COVID-19].

Authors:  Thomas Skripuletz; Nora Möhn; Christiana Franke; Harald Prüß
Journal:  Nervenarzt       Date:  2021-03-02       Impact factor: 1.214

Review 4.  Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection.

Authors:  Júlia Leão Batista Simões; Julia Beatrice de Araújo; Margarete Dulce Bagatini
Journal:  Mol Neurobiol       Date:  2021-07-11       Impact factor: 5.590

Review 5.  Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era.

Authors:  Kaja Kasarello; Dagmara Mirowska-Guzel
Journal:  Immunotargets Ther       Date:  2021-07-07

6.  COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?

Authors:  Wallace J Brownlee
Journal:  Mult Scler       Date:  2020-08-07       Impact factor: 6.312

Review 7.  Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.

Authors:  Crystal Zheng; Indrani Kar; Claire Kaori Chen; Crystal Sau; Sophia Woodson; Alessandro Serra; Hesham Abboud
Journal:  CNS Drugs       Date:  2020-09       Impact factor: 5.749

8.  Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.

Authors:  Vittorio Mantero; Damiano Baroncini; Roberto Balgera; Clara Guaschino; Paola Basilico; Pietro Annovazzi; Mauro Zaffaroni; Andrea Salmaggi; Christian Cordano
Journal:  J Neurol       Date:  2020-08-31       Impact factor: 4.849

Review 9.  The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.

Authors:  Maryam Azimzadeh; Nora Möhn; Sajjad Ghane Ezabadi; Zahra Moghimi Esfandabadi; Alireza Soleimani; Elaheh Ranjbar; Maliheh Jahromi; Reihaneh Seyedebrahimi; Thomas Skripuletz; Farshad Moharrami Kasmaie
Journal:  Biomolecules       Date:  2021-09-17

Review 10.  Impact of disease-modifying drugs on the severity of  COVID-19 infection in multiple sclerosis patients.

Authors:  Sahar Rostami Mansoor; Maryam Ghasemi-Kasman
Journal:  J Med Virol       Date:  2020-10-30       Impact factor: 20.693
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.